Clinical Trials Browser

Phase 1/2 × birtamimab × Clear all

NCT01707264 2018-08-28

Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Phase 1/2 Completed

Immunoglobulin Light-chain Amyloidosis